Search

Your search keyword '"Chester, John"' showing total 14 results
Start Over Author "Chester, John" Publisher american society of clinical oncology (asco)
14 results on '"Chester, John"'

1. Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial

Author

Birtle, Alison Jane, primary, Jones, Robert, additional, Chester, John, additional, Lewis, Rebecca, additional, Biscombe, Katie, additional, Johnson, Mark, additional, Blacker, Anthony, additional, Bryan, Richard, additional, Catto, James W.F., additional, Choudhury, Ananya, additional, Das, Prantik, additional, Jagdev, Satinder, additional, Powles, Thomas, additional, Wagstaff, John, additional, Cheung, Ka Ching, additional, Cafferty, Fay, additional, and Hall, Emma, additional

Published
2024
Full Text
View/download PDF

2. Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial

Author

Birtle, Alison Jane, Jones, Robert, Chester, John, Lewis, Rebecca, Biscombe, Katie, Johnson, Mark, Blacker, Anthony, Bryan, Richard, Catto, James W.F., Choudhury, Ananya, Das, Prantik, Jagdev, Satinder, Powles, Thomas, Wagstaff, John, Cheung, Ka Ching, Cafferty, Fay, Hall, Emma, Birtle, Alison Jane, Jones, Robert, Chester, John, Lewis, Rebecca, Biscombe, Katie, Johnson, Mark, Blacker, Anthony, Bryan, Richard, Catto, James W.F., Choudhury, Ananya, Das, Prantik, Jagdev, Satinder, Powles, Thomas, Wagstaff, John, Cheung, Ka Ching, Cafferty, Fay, and Hall, Emma

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. POUT was a phase III, randomized, open-label trial, including 261 patients with muscle-invasive or lymph node–positive, nonmetastatic upper tract urothelial cancer (UTUC) randomly assigned after radical nephroureterectomy to platinum-based chemotherapy (132) or surveillance (129). Primary outcome analysis demonstrated that chemotherapy improved disease-free survival (DFS). At that time, the planned secondary outcome analysis of overall survival (OS) was immature. By February 2022, 50 and 67 DFS events had occurred in the chemotherapy and surveillance groups, respectively, at a median follow-up of 65 months. The 5-year DFS was 62% versus 45%, univariable hazard ratio (HR) = 0.55 (95% CI, 0.38 to 0.80, P = .001). The restricted mean survival time (RMST) was 18 months longer (95% CI, 6 to 30) in the chemotherapy arm. There were 46 and 60 deaths in the chemotherapy and control arms, respectively. The 5-year OS was 66% versus 57%, with univariable HR = 0.68 (95% CI, 0.46 to 1.00, P = .049) and RMST difference 11 months (95% CI, 1 to 21). Treatment effects were consistent across chemotherapy regimens (carboplatin or cisplatin) and disease stage. Toxicities were similar to those previously reported, and there were no clinically relevant differences in quality of life between arms. In summary, although OS was not the primary outcome measure, the updated results add further support for the use of adjuvant chemotherapy in patients with UTUC, suggesting long-term benefits.

Published
2024

3. Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC).

Author

Birtle, Alison Jane, primary, Chester, John David, additional, Jones, Robert J., additional, Jenkins, Ben, additional, Johnson, Mark, additional, Catto, James WF, additional, Powles, Thomas, additional, Bryan, Richard T., additional, Blacker, Anthony, additional, Chakraborti, Prabir R, additional, Jagdev, Satinder, additional, Wagstaff, John, additional, Tolentino, Anna, additional, Webster, Luke, additional, Lewis, Rebecca, additional, and Hall, Emma, additional

Published
2021
Full Text
View/download PDF

4. Phase III randomised controlled trial (RCT) comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer (CompARE).

Author

Mehanna, Hisham Mohamed, primary, Sen, Mehmet, additional, Chester, John David, additional, Sanghera, Paul, additional, Paleri, Vinidh, additional, Gaunt, Piers, additional, Babrah, Jaspreet, additional, Hartley, Andrew G. J., additional, Kong, Anthony, additional, Al-Booz, H, additional, Foran, Bernadette, additional, Miles, Elizabeth, additional, Robinson, Max, additional, Jepson, Marcus, additional, Donnovan, Jenny, additional, Yap, Christina, additional, Firth, Charlotte, additional, Gaunt, Claire, additional, Bowden, Sarah Jane, additional, and Forster, Martin David, additional

Published
2017
Full Text
View/download PDF

5. Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer

Author

Powles, Thomas, primary, Huddart, Robert A., additional, Elliott, Tony, additional, Sarker, Shah-Jalal, additional, Ackerman, Charlotte, additional, Jones, Robert, additional, Hussain, Syed, additional, Crabb, Simon, additional, Jagdev, Satinder, additional, Chester, John, additional, Hilman, Serena, additional, Beresford, Mark, additional, Macdonald, Graham, additional, Santhanam, Sundar, additional, Frew, John A., additional, Stockdale, Andrew, additional, Hughes, Simon, additional, Berney, Daniel, additional, and Chowdhury, Simon, additional

Published
2017
Full Text
View/download PDF

6. ToTem: A phase Ib trial of temisirolimus with gemcitabine and cisplatin.

Author

Pacey, Simon, primary, Jones, Robert J., additional, Young, Alison Claire, additional, Protheroe, Andrew, additional, Birtle, Alison J., additional, Garcia Corbacho, Javier, additional, Hategan, Mirela, additional, Kumar, Sanjeev, additional, Knowles, Margaret, additional, Loadman, Paul, additional, Griffiths, Gareth, additional, Casbard, Angela Claire, additional, Madden, Tracie-Ann, additional, Adams, Richard, additional, and Chester, John David, additional

Published
2016
Full Text
View/download PDF

7. FIESTA: A phase Ib and pharmacokinetic trial of AZD4547 in combination with gemcitabine and cisplatin.

Author

Jones, Robert Hugh, primary, Anthoney, David Alan, additional, Jones, Robert J., additional, Crabb, Simon J., additional, Hussain, Syed A., additional, Birtle, Alison J., additional, Spiliopoulou, Pavlina, additional, Robinson, Timothy, additional, Knowles, Margaret, additional, McLellan, Lyndall, additional, Jones, Hazel, additional, Boylan, Zoe, additional, Landers, Donal, additional, Atuah, Kwame, additional, Sherratt, Debbie, additional, Brown, Sarah R, additional, Flanagan, Louise, additional, Loadman, Paul, additional, Twelves, Chris, additional, and Chester, John David, additional

Published
2016
Full Text
View/download PDF

8. TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin.

Author

Jones, Robert J., primary, Crabb, Simon J., additional, Chester, John D., additional, Elliott, Tony, additional, Huddart, Robert Anthony, additional, Birtle, Alison J., additional, Evans, Linda, additional, Lester, Jason Francis, additional, Huang, Chao, additional, Casbard, Angela Claire, additional, Madden, Tracie-Ann, additional, and Griffiths, Gareth, additional

Published
2016
Full Text
View/download PDF

9. A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients.

Author

Powles, Thomas, primary, Huddart, Robert Anthony, additional, Elliott, Tony, additional, Jones, Robert, additional, Hussain, Syed A., additional, Crabb, Simon J., additional, Ackerman, Charlotte, additional, Jagdev, Satinder, additional, Chester, John D., additional, Hilman, Serena, additional, Beresford, Mark, additional, Macdonald, A. Graham, additional, Sundar, Santhanam, additional, Frew, John A., additional, Stockdale, Andrew, additional, Sarker, Shah-Jalal, additional, Berney, Daniel, additional, and Chowdhury, Simon, additional

Published
2015
Full Text
View/download PDF

10. Phase II randomised placebo controlled neoadjuvant chemotherapy study of nintedanib with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer.

Author

Hussain, Syed A., primary, Jackson, Richard, additional, Shields, Alice, additional, Dickinson, Lynne, additional, Cornford, Philip, additional, Jones, Robert J., additional, Lester, Jason Francis, additional, Chester, John D., additional, Birtle, Alison J., additional, Powles, Thomas, additional, Crabb, Simon J., additional, Mazhar, Danish, additional, Huddart, Robert Anthony, additional, Protheroe, Andrew, additional, Azam, Faisal, additional, Vasudev, Naveen, additional, Butt, Mohammad, additional, and James, Nicholas David, additional

Published
2015
Full Text
View/download PDF

11. Pazopanib versus paclitaxel in relapsed urothelial tumors: A randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive transitional cell carcinoma of the urothelium (PLUTO).

Author

Jones, Robert J., primary, Chester, John D., additional, Dixon-Hughes, Judith, additional, Alexander, Laura, additional, Bahl, Amit, additional, Hussain, Syed A., additional, Birtle, Alison, additional, Jagdev, Satinder, additional, Morris, Anna, additional, Stobo, Jamie, additional, Bray, Caroline A, additional, Paul, James, additional, and Powles, Tom, additional

Published
2014
Full Text
View/download PDF

12. A national platform for molecular diagnostics: Results of the Cancer Research U.K. Stratified Medicine Programme.

Author

Shaw, Emily, primary, Butler, Rachel, additional, Gonzalez de Castro, David, additional, Griffiths, Michael, additional, Hanby, Andrew, additional, Hair, Jane, additional, Rae, Frances, additional, Rogan, Jane, additional, Morton, Dion, additional, Brenton, James, additional, Chester, John D., additional, Johnston, Stephen R. D., additional, Walker, Ian, additional, and Johnson, Peter W. M., additional

Published
2014
Full Text
View/download PDF

13. Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder.

Author

Sternberg, Cora N., primary, Skoneczna, Iwona Anna, additional, Kerst, Jan M., additional, Fossa, Sophie D., additional, Albers, Peter, additional, Agerbaek, Mads, additional, Dumez, Herlinde, additional, De Santis, Maria, additional, Theodore, Christine, additional, Leahy, Michael Gordon, additional, Chester, John D., additional, Verbaeys, Antony, additional, Caty, Armelle, additional, Daugaard, Gedske, additional, Marreaud, Sandrine, additional, Cambier, Samantha, additional, and Sylvester, Richard, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results